GSK Divests Non-Core OTCs To Focus On "Priority Brands," Emerging Markets

07 Feb 2011

• By Elizabeth Crawford

GlaxoSmithKline will divest non-core OTC products to accelerate consumer health care growth and help fund a share buy-back program following a financial wipeout in the firm's most recent quarter.

GSK Divests Non-Core OTCs To Focus On "Priority Brands," Emerging Markets

More from Archive

More from Pink Sheet